Arch Therapeutics Reports Positive Preclinical Data From Study of AC5 Surgical Hemostatic Device(TM) in Animals Treated With the Antiplatelet Medications Plavix(R) (Clopidogrel) and Aspirin
06 nov. 2014 08h57 HE
|
Arch Therapeutics, Inc.
WELLESLEY, MA--(Marketwired - Nov 6, 2014) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5 Surgical Hemostat Device ™, announced that an independent...
Arch Therapeutics Negotiating a Collaboration Agreement With CURAM Centre for Research in Medical Devices
23 oct. 2014 08h15 HE
|
Arch Therapeutics, Inc.
WELLESLEY, MA--(Marketwired - Oct 23, 2014) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5 Surgical Hemostat™, announced today that it is...
Arch Therapeutics Will Present at the Livingston Securities Life Sciences Stakeholders Summit on October 1, 2014
30 sept. 2014 08h57 HE
|
Arch Therapeutics, Inc.
WELLESLEY, MA--(Marketwired - Sep 30, 2014) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5 Surgical Hemostat™, announced that it will be featured as a...
Arch Therapeutics Co-Founder Rutledge Ellis-Behnke to Speak at 12th International Conference on Neuroprotective Agents on September 29
23 sept. 2014 08h50 HE
|
Arch Therapeutics, Inc.
WELLESLEY, MA--(Marketwired - Sep 23, 2014) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5 Surgical Hemostatic Device™ for potential use in...
Arch Therapeutics Co-Founder Rutledge Ellis-Behnke to Speak at 12th Annual Current Issues in Medicine, Biotech and Pharma Conference on September 18
16 sept. 2014 11h20 HE
|
Arch Therapeutics, Inc.
WELLESLEY, MA--(Marketwired - Sep 16, 2014) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5 Surgical Hemostatic Device™ for potential use in bleeding...
Arch Therapeutics Announces Positive Preclinical Data From an Independent Study of AC5 Surgical Hemostatic Device(TM) in Animals on Blood Thinners
08 sept. 2014 07h57 HE
|
Arch Therapeutics, Inc.
WELLESLEY, MA--(Marketwired - Sep 8, 2014) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5 Surgical Hemostatic Device™, announced that an independent...
Arch Therapeutics Will Present at the 2014 Aegis Capital Healthcare Conference in Las Vegas, NV September 10-13th, 2014
02 sept. 2014 07h58 HE
|
Arch Therapeutics, Inc.
WELLESLEY, MA--(Marketwired - Sep 2, 2014) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company") today announced it will be featured as a presenting company at the 2014 Aegis Capital...
Arch Therapeutics Will Present at the 16th Annual Rodman & Renshaw Global Investment Conference in New York City September 8-10th, 2014
26 août 2014 07h58 HE
|
Arch Therapeutics, Inc.
WELLESLEY, MA--(Marketwired - Aug 26, 2014) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), today announced it will be featured as a presenting company at the 16th Annual Rodman...
Arch Therapeutics Announces Positive Preclinical Data From Its Study of AC5 Surgical Hemostatic Device(TM) in Animals on Blood Thinner
25 août 2014 07h58 HE
|
Arch Therapeutics, Inc.
WELLESLEY, MA--(Marketwired - Aug 25, 2014) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5 Surgical Hemostatic Device™ for potential use in bleeding...
Arch Therapeutics Announces Third Quarter 2014 Results
06 août 2014 07h29 HE
|
Arch Therapeutics, Inc.
WELLESLEY, MA--(Marketwired - Aug 6, 2014) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), a life sciences company and developer of the AC5 Surgical Hemostatic...